Ganesan, Saravanan

Publications

Sort by

Co-Author Network

selected publications

JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms. Nature communications. 2025 Academic Article GET IT
A reference model of circulating hematopoietic stem cells across the lifespan with applications to diagnostics. Nature medicine. 2025 Academic Article GET IT
Times cited: 2
Single-cell mapping of regulatory DNA:Protein interactions. 2025 GET IT
Comprehensive analysis of mesenchymal cells reveals a dysregulated TGF-β/WNT/HOXB7 axis in patients with myelofibrosis. JCI insight. 2024 Academic Article GET IT
Times cited: 1
JAK2V617F-dependent down regulation of SHP-1 expression participates in the selection of myeloproliferative neoplasm cells in the presence of TGF-β. Journal of cellular and molecular medicine. 2024 Academic Article GET IT
Times cited: 2
DOGMA-seq and multimodal, single-cell analysis in acute myeloid leukemia. International review of cell and molecular biology. 2024 Review GET IT
Single-cell multi-ome and immune profiles of the Inspiration4 crew reveal conserved, cell-type, and sex-specific responses to spaceflight. Nature communications. 2024 Academic Article GET IT
Times cited: 42
Mapping genotypes to chromatin accessibility profiles in single cells. Nature. 2024 Academic Article GET IT
Times cited: 28
GoT-Splice protocol for multi-omics profiling of gene expression, cell-surface proteins, mutational status, and RNA splicing in human cells. STAR protocols. 2024 Academic Article GET IT
Times cited: 1
Cystatin F a potential diagnostic biomarker in acute promyelocytic leukemia. Annals of hematology. 2024 Letter GET IT
Times cited: 1
Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms. Blood cancer journal. 2024 Academic Article GET IT
Times cited: 9
Breast Cancer Macrophage Heterogeneity and Self-renewal are Determined by Spatial Localization. 2023 GET IT
Single-cell multi-omics defines the cell-type-specific impact of splicing aberrations in human hematopoietic clonal outgrowths. Cell stem cell. 2023 Academic Article GET IT
Times cited: 33
Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. 2022 GET IT
Times cited: 3
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal transduction and targeted therapy. 2022 Academic Article GET IT
Times cited: 138
Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia. Blood advances. 2022 Academic Article GET IT
Times cited: 11
Microenvironment and drug resistance in acute myeloid leukemia: Do we know enough?. International journal of cancer. 2021 Review GET IT
Times cited: 22
BCL-2 Inhibitor ABT-737 Effectively Targets Leukemia-Initiating Cells with Differential Regulation of Relevant Genes Leading to Extended Survival in a NRAS/BCL-2 Mouse Model of High Risk-Myelodysplastic Syndrome. International journal of molecular sciences. 2021 Academic Article GET IT
Times cited: 12
Management of relapse in acute promyelocytic leukaemia treated with up-front arsenic trioxide-based regimens. British journal of haematology. 2020 Academic Article GET IT
Times cited: 20
A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide. Cancer medicine. 2020 Academic Article GET IT
Times cited: 18
Combination Lenalidomide/Bortezomib Treatment Synergistically Induces Calpain-Dependent Ikaros Cleavage and Apoptosis in Myeloma Cells. Molecular cancer research : MCR. 2020 Academic Article GET IT
Times cited: 15
Stromal cells downregulate miR-23a-5p to activate protective autophagy in acute myeloid leukemia. Cell death & disease. 2019 Academic Article GET IT
Times cited: 36
T-Cell Protein Tyrosine Phosphatase Is Irreversibly Inhibited by Etoposide-Quinone, a Reactive Metabolite of the Chemotherapy Drug Etoposide. Molecular pharmacology. 2019 Academic Article GET IT
Times cited: 13
Prevalence of FVIII inhibitors in severe haemophilia A patients: Effect of treatment and genetic factors in an Indian population. Haemophilia : the official journal of the World Federation of Hemophilia. 2018 Academic Article GET IT
Times cited: 2
Arsenic Trioxide Enhances the NK Cell Cytotoxicity Against Acute Promyelocytic Leukemia While Simultaneously Inhibiting Its Bio-Genesis. Frontiers in immunology. 2018 Academic Article GET IT
Times cited: 15
Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia. Leukemia. 2016 Academic Article GET IT
Times cited: 31
Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance. PloS one. 2015 Academic Article GET IT
Times cited: 45
Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy. Blood. 2012 Academic Article GET IT
Times cited: 36

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Integrated single-cell multi-omics approaches to identify therapeutic vulnerabilities in VEXAS syndrome awarded by American Society of Hematology Inc Principal Investigator 2024 - 2027

Expanding the GoT toolkit to link single-cell clonal genotypes with protein, transcriptomic, epigenomic and spatial phenotypes awarded by National Cancer Institute Key Personnel 2022 - 2025
Developing Novel Therapeutic Approaches for Classical and Variant Hairy Cell Leukemia (Core 2) awarded by National Institute on Aging Key Personnel 2021 - 2025
Mosaic: post-zygotic mutations in vascular and lymphatic developmental disorders. awarded by National Institute of Allergy & Infectious Diseases Key Personnel 2020 - 2025
missing activity Key Personnel 2022 - 2023

more ...

less ...

Background

education and training

Ph.D., Sree Chitra Tirunal Institute for Medical Sciences and Technology (India) 2018
M.Sc., Madurai Kamaraj University (India) 2009
B.Sc., Thiruvalluvar University (India) 2007

VIVO Weill Cornell Medical College

Saravanan Ganesan Postdoctoral Associate in Medicine

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email